Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HA130 是选择性 autotaxin 抑制剂,IC50=28 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 297 | 现货 | ||
5 mg | ¥ 472 | 现货 | ||
10 mg | ¥ 823 | 现货 | ||
25 mg | ¥ 1,480 | 现货 | ||
50 mg | ¥ 2,490 | 现货 | ||
100 mg | ¥ 3,680 | 现货 | ||
200 mg | ¥ 5,230 | 现货 | ||
500 mg | ¥ 7,920 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 493 | 现货 |
产品描述 | HA130 is a selective ATX (autotaxin) inhibitor. |
靶点活性 | ATX:28 nM |
激酶实验 | Saturation, association, and dissociation binding studies are performed for [3H]Vilanterol to determine receptor binding kinetics at the β2-AR (equilibrium dissociation constant (KD), total number of receptors (Bmax), association rate (kon), and dissociation rate (koff) are calculated). For saturation binding, membranes (in a volume of 1.4 mL to avoid ligand depletion) are incubated with increasing concentrations of [3H]Vilanterol (~0.01-1.3 nM) for 5 h before filtration. For association binding, membranes are incubated with different concentrations of [3H]Vilanterol (~0.1-1.9 nM) for varying incubation times up to 1 h before filtration. For dissociation binding, membranes are preincubated for 1 h with a fixed concentration of [3H]Vilanterol (~1.1 nM) before dissociation is initiated by a 1:20 dilution in binding buffer (containing 10 μM cold Vilanterol) and then incubated for varying times up to 8 h before filtration. Saturation binding is also completed for [3H]CGP12177 (increasing concentrations of ~0.01-2.8 nM) in the same format as described above for [3H]Vilanterol. To determine the affinity of β2-AR agonists and antagonists, competition binding displacement studies are completed in which membranes are incubated with a fixed concentration of [3H]Vilanterol (~0.2 nM) and increasing concentrations of unlabeled agonist/antagonist for 5 h before filtration. All competition binding displacement studies are completed in the presence of 100 μM Gpp(NH)p to ensure that binding curves are monophasic[1]. |
分子量 | 463.29 |
分子式 | C24H19BFNO5S |
CAS No. | 1229652-21-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 46.33 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1585 mL | 10.7924 mL | 21.5848 mL | 53.9619 mL |
5 mM | 0.4317 mL | 2.1585 mL | 4.317 mL | 10.7924 mL | |
10 mM | 0.2158 mL | 1.0792 mL | 2.1585 mL | 5.3962 mL | |
20 mM | 0.1079 mL | 0.5396 mL | 1.0792 mL | 2.6981 mL | |
50 mM | 0.0432 mL | 0.2158 mL | 0.4317 mL | 1.0792 mL | |
100 mM | 0.0216 mL | 0.1079 mL | 0.2158 mL | 0.5396 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HA130 1229652-21-4 Metabolism PDE inhibit HA-130 HA 130 Phosphodiesterase (PDE) Inhibitor inhibitor